TrialAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.

Andre Lamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.